SFDA Calls For Re-evaluation Of High-Risk Drugs
This article was originally published in PharmAsia News
Executive Summary
China's State FDA will undertake a number of measures to strengthen supervision of drugs to enhance drug safety, including re-evaluating high-risk drugs, SFDA Deputy Director-General Wu Zhen announced in a national working-level meeting on drug safety and supervision. The re-evaluation process will start with injectable drugs. In addition, SFDA will also amend the "Statute Governing the Quality Management of Drug Manufacturing" to ensure risk management procedures are instituted. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.